Today: 11 November 2025
Subscribe
Browse Category

NASDAQ:MRNA News 22 June 2025 - 6 November 2025

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna, Inc. (NASDAQ: MRNA) posted third‑quarter 2025 revenue of ~$1.02 billion and a GAAP loss of $0.51 per share, topping Wall Street estimates as sales of its updated COVID‑19 vaccine outperformed. The company narrowed its full‑year revenue range to $1.6–$2.0 billion, cut operating‑expense guidance, and raised its year‑end cash outlook. Shares popped in pre‑market trading before wobbling intraday. SEC+1 What happened Moderna’s Q3 print outpaced expectations on both the top and bottom lines, led by stronger‑than‑modeled sales of its updated COVID‑19 shot (marketed this season as mNEXSPIKE/Spikevax 2025–26). Management simultaneously tightened the full‑year revenue band and lowered operating‑expense plans, signaling
6 November 2025
 ·  ·  ·  ·  · 
Nasdaq Rally Amid Tech Frenzy: Markets Brush Off Shutdown Fears in Late September 2025

U.S. Stock Market Today (Nov. 6, 2025): Futures Mixed as Jobless Claims & Productivity Loom; Tesla Pay Vote, Airbnb & DraftKings Earnings in Focus

Here’s your fast, fact‑checked brief on what matters before the bell in the U.S. today (Thursday, Nov. 6, 2025). 1) Overnight & pre‑market snapshot 2) Today’s U.S. economic calendar (all times ET) Why it matters: Claims set the tone for labor‑market momentum; productivity and labor‑costs feed the inflation outlook that informs the Fed’s rate‑cut path into year‑end. Reuters 3) Earnings to watch Before the open / morning: After the close / evening: 4) Stocks on the move before the bell 5) Big storylines shaping sentiment today Supreme Court scrutiny of Trump‑era tariff powers Justices signaled skepticism in Wednesday’s arguments over
6 November 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Market Performance & Buyout Rumors On Oct. 30, 2025 Moderna’s stock jumped sharply. Midday trading saw MRNA up ~11.7% to about $27.56 tradingview.com, reversing much of September–October’s slide. This followed a STAT News report (cited by Reuters) that Moderna has held buyout or partnership talks with at least one large drugmaker tradingview.com. Moderna’s shares had been languishing near all-time lows (after falling roughly 90% from pandemic highs) tradingview.com, so today’s news sparked a relief rally. Even so, with the recent gain the stock remains roughly 37% below its Jan. 2025 price tradingview.com. (By comparison, the Nasdaq and biotech indices were
30 October 2025
 ·  ·  ·  ·  · 
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Stock Rebounds on Moderna’s “Make-or-Break” Week Moderna’s stock is back in the spotlight after a turbulent week of news that sent the Nasdaq-listed shares swinging. On Wednesday, MRNA jumped over 5%, climbing to around $27.7 by market close marketbeat.com. The mini-rally came amid a flurry of developments – from upbeat trial data on a new cancer vaccine to analysts debating whether Moderna’s future is bright or bleak. Even after the pop, however, Moderna’s stock is a shadow of its former self: shares have cratered roughly 80% below last year’s levels marketbeat.com and are down one-third in 2025 alone. The once
16 October 2025
 ·  ·  ·  ·  · 
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Detailed Report 1. Stock Performance and Valuation Moderna’s stock was a market darling during the pandemic but has suffered a long decline. On Oct 7 2025 (the last trading day before the U.S. Columbus Day holiday), the stock closed at $27.34, down roughly 0.7% from $27.54 on the prior session stockinvest.us. Technical analysts at Stockinvest.us noted the shares were near the upper part of a wide falling trend and predicted a possible trading range of $26.40–$28.73 on Oct 8, with longer‑term support around $26 and resistance near $31 stockinvest.us. While short‑term signals were positive, they cautioned that the overall downward trend remains stockinvest.us.
8 October 2025
 ·  ·  ·  ·  ·  ·  · 
Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Pfizer Inc., in collaboration with BioNTech, co-developed the first FDA-approved mRNA COVID-19 vaccine, Comirnaty. Roche Holding AG is the world’s largest biotech company and a leader in oncology treatments (Herceptin) and diagnostics. Moderna, Inc. pioneered mRNA vaccine technology and its COVID-19 vaccine was among the first mRNA medicines approved, while expanding mRNA therapeutics for cancer and rare diseases. Illumina, Inc. is a market leader in DNA sequencing with platforms such as NovaSeq that enabled the concept of a $1,000 genome. CRISPR Therapeutics AG is a leading CRISPR-Cas9 gene editing company developing exa-cel for sickle cell disease and other therapies. Ginkgo
22 June 2025
 ·  ·  ·  ·  ·  ·  ·  ·  ·  ·  · 
Go toTop